Long-serving Roche chief executive Severin Schwan is stepping down, to be replaced next March by Thomas Schinecker, currently head of diagnostics at the Swiss group. Schwan (pictured above) has ...

Armed with the new data, Roche has decided to start a phase 3 trial comparing a tiragolumab, Tecentriq, and bevacizumab triplet to Tecentriq/bevacizumab in this patient setting in the coming months.